Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Anastrozole and fulvestrant in metastatic breast cancer.

Ramaekers R, Jabbour M, Copur MS.

N Engl J Med. 2012 Oct 25;367(17):1662-3; author reply 1663-4. doi: 10.1056/NEJMc1210463#SA2. No abstract available.

PMID:
23094733
2.

Anastrozole and fulvestrant in metastatic breast cancer.

Tempfer C.

N Engl J Med. 2012 Oct 25;367(17):1663; author reply 1663-4. doi: 10.1056/NEJMc1210463#SA3. No abstract available.

PMID:
23094734
3.

Anastrozole and fulvestrant in metastatic breast cancer.

Lintermans A, Vanderhaegen J, Neven P.

N Engl J Med. 2012 Oct 25;367(17):1662; author reply 1663-4. doi: 10.1056/NEJMc1210463#SA1. No abstract available.

PMID:
23094732
4.

Breast cancer: Anastrozole and fulvestrant--combination to unlock efficacy.

Goldhirsch A, Gelber RD.

Nat Rev Clin Oncol. 2012 Oct;9(10):556-7. doi: 10.1038/nrclinonc.2012.155. Epub 2012 Sep 4. No abstract available.

PMID:
22949048
5.

Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven.

Di Leo A, Malorni L.

J Clin Oncol. 2012 Jun 1;30(16):1897-900. doi: 10.1200/JCO.2012.41.7394. Epub 2012 Apr 30. No abstract available.

6.

Fulvestrant versus anastrozole as second-line treatment of advanced breast cancer in postmenopausal women.

Vergote I; Faslodex 0020 and 0021 Investigators.

Eur J Cancer. 2002 Nov;38 Suppl 6:S57-8. No abstract available.

PMID:
12409076
7.

Plasma levels of tamoxifen, N-desmethyl tamoxifen and anastrozole in a patient with metastatic breast cancer and chronic hemodialysis.

Langenegger T, Wahl P, Schiesser D, Thürlimann B.

Breast Cancer Res Treat. 2006 Nov;100(2):177-81. Epub 2006 May 11.

PMID:
16688477
8.

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer.

Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO, Channon E, Hyman-Taylor P, Nicholson RI, Gee JM.

Breast Cancer Res. 2013 Mar 5;15(2):R18. doi: 10.1186/bcr3393.

9.

Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

Carlson RW, Theriault R, Schurman CM, Rivera E, Chung CT, Phan SC, Arun B, Dice K, Chiv VY, Green M, Valero V.

J Clin Oncol. 2010 Sep 1;28(25):3917-21. doi: 10.1200/JCO.2009.24.9565. Epub 2010 Aug 2.

10.

A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma.

Zagouri F, Dimitrakakis C, Dimopoulos MA, Tsigginou A, Antsaklis A, Papadimitriou CA.

Breast J. 2012 Nov-Dec;18(6):628-9. doi: 10.1111/tbj.12019. Epub 2012 Sep 26. No abstract available.

PMID:
23009609
11.

'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.

Buzdar AU; ATAC trialists' group.

J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):399-403.

PMID:
14623537
12.

Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.

Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G.

J Clin Oncol. 2007 Jul 1;25(19):2664-70. Epub 2007 Jun 11.

13.

Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.

Watanabe N, Ootawa Y, Kodama K, Kaide A, Ootsuka N, Matsuoka J.

Breast Cancer. 2010 Oct;17(4):247-53. doi: 10.1007/s12282-009-0144-6. Epub 2009 Sep 1.

PMID:
19728030
14.

Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.

Buzdar A.

Clin Breast Cancer. 2003 Apr;4 Suppl 1:S42-8. Review.

PMID:
12756078
15.

[Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer].

Yao SY, Xu BH, Li Q, Zhang P, Wang JY, Yuan P, Ma F, Cai RG.

Zhonghua Yi Xue Za Zhi. 2010 Mar 2;90(8):526-8. Chinese.

PMID:
20367963
16.

Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.

Krell J, Ewart EK, Stebbing J.

Eur J Cancer. 2010 Nov;46(16):2867-9. doi: 10.1016/j.ejca.2010.08.021. Epub 2010 Sep 27. No abstract available.

PMID:
20880696
17.

Update on ATAC.

[No authors listed]

Eur J Cancer. 2003 Feb;39(3):269. No abstract available.

PMID:
12632577
18.
19.

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.

Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Iwata H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y.

Breast Cancer Res Treat. 2010 Jun;121(2):379-87. doi: 10.1007/s10549-010-0888-x.

PMID:
20390343
20.

Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).

Takei H, Ohsumi S, Shimozuma K, Takehara M, Suemasu K, Ohashi Y, Hozumi Y.

Breast Cancer Res Treat. 2012 May;133(1):227-36. doi: 10.1007/s10549-011-1943-y. Epub 2012 Jan 11.

PMID:
22234519
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk